Skip to main content
. 2023 Nov 6;83(2):177–183. doi: 10.1136/ard-2023-224356

Figure 2.

Figure 2

Pooled analysis of NMSC RRs for abatacept versus other b/tsDMARDs. RABBIT did not run RRs for this comparison. A random-effects model was used to address heterogeneity. The RRs were calculated separately in each database and a pooled estimate was conducted. ARTIS, Anti-Rheumatic Therapy in Sweden; b/tsDMARD, biological/targeted synthetic disease-modifying antirheumatic drug; FORWARD, The National Databank for Rheumatic Diseases; MarketScan, Truven MarketScan Commercial and Supplemental Medicare; NMSC, non-melanoma skin cancer; Optum, Optum Clinformatics Data Mart; PharMetrics, IMS PharMetrics; RABBIT, Rheumatoid Arthritis Observation of Biologic Therapy; RR, rate ratio.